Yujing Tan

Chinese Academy Of Medical Sciences & Peking Union Medical College
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective study.

Journal: Cancer biology & therapy

Published: June 23, 2026

Clinical Advances in Breast Cancer: A Comprehensive Overview of Full-Course Disease Management.

Clinical Advances in Breast Cancer: A Comprehensive Overview of Full-Course Disease Management.

Journal: Cancer innovation

Published: February 09, 2026

Spatial transcriptome revealed associated biomarkers for endocrine therapy response in HR-positive/HER2-negative early breast cancer.

Spatial transcriptome revealed associated biomarkers for endocrine therapy response in HR-positive/HER2-negative early breast cancer.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: December 10, 2025

Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer.

Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer.

Journal: Breast cancer (Dove Medical Press)

Published: October 23, 2025

Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer.

Potential Targets and Biomarkers of Radionuclide Therapy in Breast Cancer.

Journal: Cancer innovation

Published: September 15, 2025

Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial.

Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial.

Journal: Cancer letters

Published: August 27, 2025

A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion.

A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion.

Journal: International journal of cancer

Published: May 21, 2025

Pre-Treatment Ki67 Index for Everolimus Efficacy in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter Cohort Study.

Pre-Treatment Ki67 Index for Everolimus Efficacy in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter Cohort Study.

Journal: Cancer research and treatment

Published: May 12, 2025

Novel Causal Evidence for the Role of Circulating Lipid Metabolites in Breast Cancer Risk: A Bidirectional Mendelian Randomization Analysis.

Novel Causal Evidence for the Role of Circulating Lipid Metabolites in Breast Cancer Risk: A Bidirectional Mendelian Randomization Analysis.

Journal: Journal of nutrition and metabolism

Published: March 08, 2025

Case Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancer.

Case Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancer.

Journal: Frontiers in immunology

Published: March 07, 2025

Multi-cohort validation of a lipid metabolism and ferroptosis-associated index for prognosis and immunotherapy response prediction in hormone receptor-positive breast cancer.

Multi-cohort validation of a lipid metabolism and ferroptosis-associated index for prognosis and immunotherapy response prediction in hormone receptor-positive breast cancer.

Journal: International journal of biological sciences

Published: March 04, 2025

Lysine Acetyltransferase 6 in Health and Disease.

Lysine Acetyltransferase 6 in Health and Disease.

Journal: MedComm

Published: January 09, 2025

Showing 1-12 of 18

Last Updated: 09/26/2026